Our news

Imcyse Announces Completion of Enrollment

01. March 2023

Liège, Belgium, March 1st 2023 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of patient enrollment in its Phase 2 IMPACT (IMCY-0098 Proof of ACtion in Type 1 Diabetes) trial of its lead product candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to halt the progression and prevent early-onset Type 1 diabetes (T1D).

“Type 1 diabetes is a debilitating, lifelong disease linked to a multitude of other problems that impact overall health. There remains a critical unmet need for effective prevention strategies or causal therapies beyond insulin replacement that can improve patient quality of life,” commented Prof. Dr. Chantal Mathieu Principal Investigator of the IMPACT study and Coordinator at T1D consortium INNODIA.